Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...
Morning Overview on MSN
The new pancreatic cancer drug works by jamming a protein long thought undruggable
A drug that locks onto an active form of the RAS protein, a target that researchers spent decades trying and failing to hit, extended survival for patients with previously treated metastatic ...
A blue protein ribbon structure labeled PI3Kα has a space-filling molecule bound to it, which interacts (clashes) with a second protein ribbon molecule labeled KRas. This model shows how BBO-10203 ...
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results